Drugs / gp160MN/LAI-2
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00004579 | Apr 1998 → ? | HIV infectious disease | Walter Reed Army Institute of Research (WRAIR) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | gp160MN/LAI-2 | “A Phase I, Dose-Ranging Trial of the Pasteur Merieux Connaught (PMC) Oligomeric HIV-1 gp160MN/LAI-2 Vaccine Alone or Primed With Live Recombinant ALVAC-HIV (vCP205) in HIV...” NCT00004579 ↗ |
| Known as | ogp160 MN/LAI-2 | “received oligomeric glycoprotein 160 from HIV strains MN and LAI-2 (ogp160 MN/LAI-2) with dose escalation (25, 50, 100 μg)” PMID 26908741 ↗ Feb 2016 |
| Modality | Vaccine | “The vCP205 vaccine will be tested with another vaccine, gp160MN/LAI-2.” NCT00004579 ↗ |